Daratumumab for use in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma wo have received at least one prior therapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||09/10/2017|
|Rapid review completed||27/11/2017|
|Rapid Review outcome||A full pharmacoeconomic evaluation is recommended|
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.